Gerresheimer - Comprehensive Analysis Report
Summary
Gerresheimer AG is a German manufacturer specializing in primary packaging products for medication and drug delivery devices composed of special-purpose glass and plastics. Serving the pharmaceutical and cosmetics industries, the company was established in 1864 by Ferdinand Heye and has evolved into a global provider of healthcare and beauty solutions. Gerresheimer is committed to sustainability, aiming to use 100% renewable electricity by 2030 and reduce its carbon footprint.
1. Strategic Focus & Objectives
Core Objectives
- To be the leading global partner for enabling solutions that improve health and well-being.
- Focus on customer centricity, innovation, and operational excellence.
- Shift the portfolio from volume to value and expand margins.
- Expand its portfolio of primary packaging, closures, accessories, and drug delivery systems.
- Invest in margin-enhancing growth projects.
- Focus on high-value solutions and medical devices.
- Grow in biologics solutions and injectables.
Specialization Areas
- Primary packaging for medication
- Drug delivery devices
- Special-purpose glass and plastics
- Solutions for the Pharmaceutical and Cosmetics industries
- High-value solutions and medical devices
- Biologics solutions and injectables
Target Markets
- Pharmaceutical industry
- Biotech industry
- Diagnostics
- Medical technology
- Cosmetics industries
- Europe
- Americas
- Asia
2. Financial Overview
Funding History
- In August 2025, Gerresheimer secured loans of EUR 200 million to repay part of the bridge financing for the acquisition of the Bormioli Pharma Group.
- Revenues in 2023 reached €1.99 billion, with an adjusted EBITDA of €404.5 million.
- Gerresheimer is aiming for positive free cash flow in 2026.
- The company is listed in the MDAX on the Frankfurt Stock Exchange.
3. Product Pipeline
Key Products/Services
- SensAIR: A drug delivery device with precise dosing and real-time monitoring capabilities.
- Respimetrix: A monitoring device that captures data on lung function.
- Gx InnoSafe: A safety syringe.
- Gx Inbeneo: An autoinjector designed for home use.
4. Technology & Innovation
Technology Stack
- Gx Cap: A connected cap, distributed via Centor, that monitors medication adherence.
- Connected Packaging Solutions: Utilizing QR codes and NFC tags to create digital customer touchpoints.
- formula Operations: A strategy focused on all areas of production, including occupational safety, quality performance, and automation.
- Proprietary technologies: Connected prescription vial closure devices and cloud-based software through RxCap partnership.
- Significant scientific methods: Advanced algorithms and sensors for targeted drug delivery, and data-driven business models for healthcare.
5. Leadership & Management
Executive Team
- Dietmar Siemssen: Chief Executive Officer for Plastics & Devices and Advanced Technologies Division.
- Bernd Metzner: Chief Financial Officer.
- Lukas Burkhardt: Head of Primary Packaging Glass.
- Axel Herberg: Chairman of the company.
- Markus Romer: Deputy Chairman.
Recent Leadership Changes
- Lukas Burkhardt was appointed to the Management Board of Gerresheimer AG effective January 1, 2018.
- Bernd Metzner has been the Chief Financial Officer of the company since 2019.
6. Competitive Analysis
Major Competitors
- Schott
- Consort Medical
- Phillips-Medisize Corporation
- West Pharmaceutical Services
- Aptar
- Stevanato Group
7. Market Analysis
Market Overview
- Gerresheimer operates in the pharmaceutical, biotech, diagnostics, medical technology, and cosmetics industries.
- The company has a presence in Europe, the Americas, and Asia.
- Sustainability is a key driver.
8. Strategic Partnerships
- RxCap: Partnership to offer connected adherence solutions; Gerresheimer acquired a minority stake.
- Midas Pharma: Strategic partnership for the development and marketing of a new generation autoinjector.
- Portal Instruments: Collaboration to commercialize the Prime NEXUS™ reusable autoinjector platform.
9. Operational Insights
- Gerresheimer is focused on transitioning to a system and solution provider for the pharmaceutical and biotech industries.
- The company is working to expand its portfolio of primary packaging, closures, accessories, and drug delivery systems.
- Gerresheimer is investing in modern production technologies.
- The company is separating its Molded Glass business to focus on pharmaceutical and biotech industries.
10. Future Outlook
Strategic Roadmap
- Gerresheimer aims to strengthen its position as a system and solution provider.
- The company plans to develop products for biologics and expand its portfolio of primary packaging, closures, and drug delivery systems.
- Gerresheimer is focused on customer-centric, data-driven business models.
